[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
|
[2] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2018, 68(6):394-424.
|
[3] |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
[4] |
Bosetti C, Turati F, La Vecchia C. HepatocelIular carcinoma epidemiology[J]. Best Pract Res CIin Gastroenterol, 2014, 28(5):753-770.
|
[5] |
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-con-trolled trial[J].Lancet Oncol, 2015, 16(13):1344-1354.
|
[6] |
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J].中华消化外科杂志, 2020, 19(1):1-20.
|
[7] |
Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma[J]. Ann Surg, 2004, 240(2):299-305.
|
[8] |
张志伟, 陈孝平. 肝细胞癌外科手术方式的选择[J]. 临床外科杂志, 2021, 29(1):4-6.
|
[9] |
Fang C, Zhang P, Qi X. Digital and intelligent liver surgery in the new era: prospects and dilemmas[J]. EBioMedicine, 2019(41):693-701.
|
[10] |
Urade T, Sawa H, Iwatani Y, et al. Laparoscopic anatomical liver resection using indocyanine green fluorescence imaging[J]. Asian J Surg, 2020, 43(1):362-368.
|
[11] |
汪国营. 肝癌肝移植新进展——2019年ILTS年会速递[J]. 器官移植, 2020, 11(1):47-53.
|
[12] |
Sato T, Takahashi Y, Imai M, et al. Hepatic arterial infusion chemotherapy using a reservoir for advanced hepatocellular carcinoma[J]. Gan To Kagaku Ryoho, 2016, 43(1):73-77.
|
[13] |
Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis[J]. Hepatology, 2018, 67(1):381-400.
|
[14] |
陈敏山, 元云飞, 郭荣平, 等. 肝动脉灌注化疗在肝癌转化治疗中的应用——中山大学肿瘤防治中心的经验总结[J/CD]. 中国医学前沿杂志(电子版), 2021, 13(3):70-76.
|
[15] |
Zhang Y, Huang G, Wang Y, et al. Is salvage liver resection necessary for initially unresectable hepatocellular carcinoma patients downstaged by transarterial chemoembolization? ten years of experience[J]. Oncologist, 2016, 21(12):1442-1449.
|
[16] |
Kim Y, Stahl CC, Makramalla A, et al. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria[J]. Surgery, 2017, 162(6):1250-1258.
|
[17] |
He MK, Le Y, Li QJ, et al. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study[J]. Chin J Cancer, 2017, 36(1):83.
|
[18] |
Nagamat H, Sumie S, Niizeki T, et al. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phaseⅡ study[J]. Cancer Chemother Pharmacol, 2016, 77(2):243-250.
|
[19] |
Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial[J]. Int J Cancer, 2015, 136(6):1458-1467.
|
[20] |
Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phaseⅢ randomized controlled trial[J]. Gut, 2017, 66(6):1172-1173 .
|
[21] |
柳明, 刘超, 李成利, 等. 影像引导肝癌的冷冻消融治疗专家共识(2020版)[J]. 中国医刊, 2020, 55(5):489-492.
|
[22] |
李鑫, 梁萍. 超声引导下肝癌热消融治疗的现状与进展[J]. 临床肝胆病杂志, 2021, 37(3):510-514.
|
[23] |
成剑, 张远标, 范小明, 等. 经皮微波消融肝实质分隔联合门静脉栓塞治疗肝硬化晚期肝癌的补救性治疗策略探讨[J]. 中华普通外科杂志, 2020, 35(1):77-79.
|
[24] |
Lau WY, Teoh YL, Win KM, et al. Current role of selective internal radiation with yttrium-90 in liver tumors[J]. Future Oncol, 2016, 12(9):1193-1204.
|
[25] |
刘允怡, 赖俊雄, 刘晓欣. 钇90微球治疗原发性肝癌[J]. 临床肝胆病杂志, 2011, 27(4):348-350.
|
[26] |
Wang TH, Huang PI, Hu YW, et al. Combined Yttrium-90 mierosphere selective intemal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: from clinical aspects to dosimetry[J]. PloS One, 2018, 13(1):e0190098.
|
[27] |
刘书勋, 王嘉倍, 刘连新. 钇90微球选择性放疗栓塞在肝癌治疗中的应用[J]. 中国现代普通外科进展, 2019, 22(7):540-542, 582.
|
[28] |
Abbasakoor F, Singhvi R, Roberts A, et al. Portal vein embolism[J].J R Soc Med, 1999, 92(4):197-198.
|
[29] |
赵文超, 吴印涛, 杨英祥, 等. 肝动脉插管化疗栓塞联合选择性门静脉栓塞后手术切除治疗大肝癌的安全性和有效性观察[J]. 中华肝胆外科杂志, 2021, 27(3):164-168.
|
[30] |
刘允怡, 刘晓欣. 对"联合肝脏离断和门静脉结扎的二步肝切除术"的述评[J]. 中华消化外科杂志, 2013, 12(7):481-484.
|
[31] |
彭远飞, 王征, 周俭. 联合肝脏分隔和门静脉结扎二步肝切除术治疗传统不可切除肝癌之进展[J]. 中华消化外科杂志, 2021, 20(2):155-162.
|
[32] |
Cheng H, Sun G, Chen H, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies[J]. Am J Cancer Res, 2019, 9(8):1536-1545.
|
[33] |
张雯雯, 胡丙洋, 韩骏, 等. PD-1抑制剂与多靶点酪氨酸激酶抑制剂联合方案用于进展期肝癌转化治疗研究的初步报告[J]. 中华肝胆外科杂志, 2020, 26(12):947-948.
|
[34] |
黄缘, 董家鸿. 乙型肝炎病毒和丙型肝炎病毒相关性肝细胞肝癌围手术期抗病毒治疗进展[J]. 中华肝脏病杂志, 2017, 25(1):73-76.
|
[35] |
朱武刚, 陆晓兰, 刘洪涛, 等. 肝癌根治术后辅助TACE疗效的meta分析[J]. 介入放射学杂志, 2019, 28(9):865-869.
|
[36] |
中国医学科学院北京协和医学院肿瘤医院消化道肿瘤多学科协作组. 肝癌靶向治疗专家共识(草案)[J/CD]. 肝癌电子杂志, 2020, 7(2):2-11.
|
[37] |
2019年肝癌中西医临床协作专家委员会. 原发性肝癌微创消融联合中医诊疗专家共识[J/CD]. 中华介入放射学电子杂志, 2021, 9(1):9-19.
|
[38] |
陈怡, 曾玲, 杨沁, 等. 营养支持治疗对肝癌患者术后应激指标、营养状况、远期生存率的影响[J]. 中国肿瘤外科杂志, 2020, 12(3):228-232.
|
[39] |
中国抗癌协会肝癌专业委员会. 中国肝癌多学科综合治疗专家共识[J]. 临床肝胆病杂志, 2021, 37(2):278-285.
|